{
  "id": 16128382,
  "title": "L'Oreal says weight loss drugs are impacting beauty and skin care sales",
  "url": "https://urgent.news/2026/10/22/loreal-says-weight-loss-drugs-are-impacting-beauty-and-skin-care-sales",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-22T22:27:53.000Z",
  "source": {
    "name": "BBC Business",
    "slug": "bbc-business",
    "url": "https://www.bbc.co.uk/news/articles/cvglwgwpgrlpo?at_medium=RSS&at_campaign=rss"
  },
  "original_language": "en",
  "account": "Loreal, a major beauty company, has reported that the surge in popularity of weight loss drugs is affecting beauty and skin care sales. Nicolas Hieronimus, the company's CEO, stated that the beauty market is remaining resilient despite a challenging global context. The rise in the use of GLP-1 drugs, which are primarily used to treat diabetes but also lead to significant weight loss by suppressing appetite, is impacting beauty and skin care consumption, particularly. The company, which owns brands such as Maybelline and La Roche-Posay, reported a 7.7% increase in sales for the three months ending September, surpassing analyst expectations.\n\nThe growing popularity of GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro, has coincided with an increase in side effects such as loose skin, particularly around the face. Loreal has responded by designing products specifically to address these side effects and complement the effects of GLP-1 drugs. Specifically, their brands SkinCeuticals and Kiehl's offer products that cater to this market. Additionally, the company has expanded its presence in the clinical aesthetic space by increasing its stake in dermatology firm Galderma to 20%. Both Loreal and Galderma have been conducting clinical trials to test products on GLP-1 users who are concerned about loose skin.\n\nGalderma, which owns popular aesthetic products like Sculptra and Restylane, released a report last year highlighting the rise in GLP-1 use and the related concerns about changes in facial appearance. A survey conducted by Galderma found that the majority of users of these weight loss medications noticed changes to their facial appearance after using these drugs.",
  "summary": "The beauty giant's CEO says the use of GLP-1s is \"a very important phenomenon for us\".",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}